Efficacy and Safety Study of Udenafil to Treat Erectile Dysfunction
NCT ID: NCT01774864
Last Updated: 2013-01-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
349 participants
INTERVENTIONAL
2011-04-30
2012-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
parallel group, fixed dose design
Phase : Phase III
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Study of Once-a-Day Dosing of Udenafil to Treat Erectile Dysfunction
NCT01901640
Treatment of Erectile Dysfunction I
NCT01037244
Treatment of Erectile Dysfunction II
NCT01037218
Treatment of Erectile Dysfunction - Long Term Safety and Efficacy
NCT01065012
A Study of DA-8159 in Subjects With Erectile Dysfunction
NCT00282607
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DA-8159 dose 1
Udenafil
DA-8159 (Udenafil)
DA-8159 dose 2
Udenafil
DA-8159 (Udenafil)
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DA-8159 (Udenafil)
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Had hepatic or renal dysfunction
* Was currently under anticancer chemotherapy
* Had a treatments for ED using other PDE-5 inhibitors
20 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dong-A Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
S W Kim, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
the Catholic University of Korea St. Mary's Hospital
D G Moon, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Korea University Guro Hospital
J J Kim, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Korea University Anam Hospital
N C Park, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Pusan National University Hospital
S W Lee, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
J S Paick, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
T Y Ahn, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
K H Moon, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Yeungnam University Hospital
W S Chung, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Ewha Womans University
K S Min, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Inje University
J K Park, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Chonbuk National University Hospital
D Y Yang, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Kangdong Sacred Heart Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DA8159_EDD_III
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.